Results 11 to 20 of about 6,425 (142)

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis [PDF]

International Journal of Cardiology: Heart & Vasculature, 2021
Objectives: Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family. It is raised in various cardiovascular diseases, but its value in predicting disease severity or mortality outcomes has been controversial ...
Christina Ip, King Sum Luk, Vincent Lok Cheung Yuen, Lorraine Chiang, Ching Ki Chan, Kevin Ho, Mengqi Gong, Teddy Tai Loy Lee, Keith Sai Kit Leung, Leonardo Roever, George Bazoukis, Konstantinos Lampropoulos, Ka Hou Christien Li, Gary Tse, Tong Liu   +14 more
doaj   +2 more sources

Association between soluble suppression of tumorigenicity 2 and risk and severity of coronary artery disease: a case control study [PDF]

BMC Cardiovascular Disorders
Background To investigate the differential expression of soluble suppression of tumorigenicity 2 (sST2) in patients with coronary artery disease (CAD) and healthy controls, and the correlation between sST2 and the severity of coronary artery ...
Shuai Zhang, Lu Qian, Shibao Li, Zhijian Liu   +3 more
doaj   +2 more sources

Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range [PDF]

Diabetes, Metabolic Syndrome and Obesity, 2020
Amal Hasan,1 Waleed Aldhahi2,3 1Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait; 2Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 3Department of Medicine, Mubarak Al-Kabeer Hospital, Kuwait City,
Hasan A, Aldhahi W
doaj   +2 more sources

Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure [PDF]

Frontiers in Cardiovascular Medicine, 2022
BackgroundBoth β1 adrenergic receptor autoantibody (β1-AA) and soluble suppression of tumorigenicity-2 (sST2) take a role in the pathological remodeling of heart failure.
Yanxiang Sun, Li Feng, Bing Hu, Jianting Dong, Liting Zhang, Xuansheng Huang, Yong Yuan   +6 more
doaj   +2 more sources

Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis [PDF]

BMC Gastroenterology
Background & aims With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis.
Florian F. Hildenbrand, Barbara Illi, Stefanie von Felten, Jacqueline Bachofner, Joanna Gawinecka, Arnold von Eckardstein, Beat Müllhaupt, Joachim C. Mertens, Sena Blümel   +8 more
doaj   +2 more sources

Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction [PDF]

BMC Cardiovascular Disorders
Background Microvascular obstruction (MVO) develops in approximately 50% of patients with ST-segment elevation myocardial infarction (STEMI) after undergoing percutaneous coronary intervention (PCI).
Xinjia Du, Jiahua Liu, Jingfang Zhou, Yanfei Ren, Nauman Gul, Lei Chen, Yuan Lu   +6 more
doaj   +2 more sources

Circulating soluble suppression of tumorigenicity-2 and the recurrence of atrial fibrillation after catheter ablation: A meta-analysis [PDF]

Biomolecules & Biomedicine
Soluble suppression of tumorigenicity-2 (sST-2), a marker of myocardial fibrosis and remodeling, has been related to the development of atrial fibrillation (AF). The aim of this meta-analysis was to evaluate the relationship between baseline serum sST-2
Yanyu Shi, Zepeng Zhang, Tianyang Zhang, Linlin Zhang, Shan An, Ying Chen   +5 more
doaj   +2 more sources

Soluble suppression of tumorigenicity-2 changes during cardiotoxic cancer treatment: a systematic review and meta-analysis [PDF]

Frontiers in Cardiovascular Medicine
BackgroundSoluble suppression of tumorigenicity-2 (sST2) is a promising biomarker of cardiovascular disease and heart failure. Data about the changes in sST2 concentrations during cancer treatment and the relationship with cancer treatment-related ...
Luca Fazzini, Simone Angius, Nicola Campana, Luca Pascalis, Martino Deidda, Giordano Maria Pugliesi, Giordano Maria Pugliesi, Vincenzo Quagliariello, Nicola Maurea, Carlo Gabriele Tocchetti, Carlo Gabriele Tocchetti, Carlo Gabriele Tocchetti, Carlo Gabriele Tocchetti, Pietro Ameri, Pietro Ameri, Christian Cadeddu Dessalvi   +15 more
doaj   +2 more sources

Soluble suppression of tumorigenicity 2 associated with left ventricular thrombosis in patients with ST-segment elevation myocardial infarction [PDF]

BMC Cardiovascular Disorders
Background Left ventricular thrombosis (LVT) after acute ST-segment elevation myocardial infarction (STEMI) is closely related to inflammation. Soluble Suppression of Tumorigenicity 2 (sST2) expressed as a novel inflammatory marker, has received much ...
Xinjia Du, Perkash Kumar, Chen Liu, Jiahua Liu, Lei Chen, Yuan Lu, Zhuoqi Zhang   +6 more
doaj   +2 more sources

Soluble suppression of tumorigenicity 2 is a potential predictor of post-liver transplant renal outcomes [PDF]

PLoS ONE, 2023
Jong Joo Moon, Suk Kyun Hong, Yong Chul Kim, Su young Hong, YoungRok choi, Nam-Joon Yi, Kwang-Woong Lee, Seung Seok Han, Hajeong Lee, Dong Ki Kim, Yon Su Kim, Seung Hee Yang, Kyung-Suk Suh   +12 more
doaj   +2 more sources